These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17363532)

  • 41. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
    Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
    Le Tourneau C; Faivre S; Laurence V; Delbaldo C; Vera K; Girre V; Chiao J; Armour S; Frame S; Green SR; Gianella-Borradori A; Diéras V; Raymond E
    Eur J Cancer; 2010 Dec; 46(18):3243-50. PubMed ID: 20822897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hidalgo M; Siu LL; Nemunaitis J; Rizzo J; Hammond LA; Takimoto C; Eckhardt SG; Tolcher A; Britten CD; Denis L; Ferrante K; Von Hoff DD; Silberman S; Rowinsky EK
    J Clin Oncol; 2001 Jul; 19(13):3267-79. PubMed ID: 11432895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
    Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
    Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG
    J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R; Bissett D; Twelves C; Breimer L; DeMario M; Campbell S; Zhi J; Ritland S; Cassidy J
    Clin Cancer Res; 2004 Jul; 10(13):4374-82. PubMed ID: 15240525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
    Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
    Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
    Dowlati A; Hoppel CL; Ingalls ST; Majka S; Li X; Sedransk N; Spiro T; Gerson SL; Ivy P; Remick SC
    J Clin Oncol; 2001 Apr; 19(8):2309-18. PubMed ID: 11304785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
    Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
    Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
    Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
    Yap TA; Yan L; Patnaik A; Tunariu N; Biondo A; Fearen I; Papadopoulos KP; Olmos D; Baird R; Delgado L; Tetteh E; Beckman RA; Lupinacci L; Riisnaes R; Decordova S; Heaton SP; Swales K; deSouza NM; Leach MO; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
    Clin Cancer Res; 2014 Nov; 20(22):5672-85. PubMed ID: 25239610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
    Tevaarwerk A; Wilding G; Eickhoff J; Chappell R; Sidor C; Arnott J; Bailey H; Schelman W; Liu G
    Invest New Drugs; 2012 Jun; 30(3):1039-45. PubMed ID: 21225315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
    Bailey HH; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Simon K; Marnocha R; Holstein SA; Stewart J; Lewis KA; Hohl RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):368-76. PubMed ID: 15205914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
    Berlin J; Tutsch KD; Arzoomanian RZ; Alberti D; Binger K; Feierabend C; Dresen A; Marnocha R; Pluda J; Wilding G
    Clin Cancer Res; 2002 Jan; 8(1):86-94. PubMed ID: 11801543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
    Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
    Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
    Gartner EM; Silverman P; Simon M; Flaherty L; Abrams J; Ivy P; Lorusso PM
    Breast Cancer Res Treat; 2012 Feb; 131(3):933-7. PubMed ID: 22083229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
    Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
    Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
    Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
    Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.